Omnicell (NASDAQ:OMCL) Stock Gets Downgrade from Wall Street Zen

Omnicell (NASDAQ:OMCL) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report released on Saturday, Wall Street Zen reports.

Other equities analysts have also issued research reports about the stock. Zacks Research upgraded shares of Omnicell from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 4th. Piper Sandler reiterated an “overweight” rating and set a $45.00 price target (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. Wells Fargo & Company decreased their price target on Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, July 31st. KeyCorp reissued an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Finally, Weiss Ratings raised Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $57.86.

Omnicell Price Performance

Omnicell stock opened at $37.34 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.45 and a current ratio of 1.65. Omnicell has a 52-week low of $31.75 and a 52-week high of $55.00. The firm has a 50 day moving average price of $34.93 and a two-hundred day moving average price of $38.78. The firm has a market cap of $1.72 billion, a price-to-earnings ratio of 38.90, a PEG ratio of 0.93 and a beta of 0.88.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, October 29th. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.16. Omnicell had a net margin of 3.59% and a return on equity of 5.69%. The firm had revenue of $307.85 million for the quarter, compared to the consensus estimate of $304.44 million. During the same quarter in the previous year, the company earned $0.51 EPS. The company’s revenue for the quarter was down .9% on a year-over-year basis. Equities analysts predict that Omnicell will post 1.64 EPS for the current year.

Institutional Trading of Omnicell

Hedge funds have recently modified their holdings of the stock. Nykredit A S bought a new stake in Omnicell in the 2nd quarter valued at about $26,000. Versant Capital Management Inc raised its stake in Omnicell by 38.7% during the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after buying an additional 294 shares during the period. Fulcrum Asset Management LLP boosted its holdings in Omnicell by 2,536.4% in the third quarter. Fulcrum Asset Management LLP now owns 1,160 shares of the company’s stock worth $40,000 after acquiring an additional 1,116 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new position in Omnicell in the second quarter worth approximately $105,000. Finally, Nisa Investment Advisors LLC boosted its holdings in Omnicell by 21.9% in the third quarter. Nisa Investment Advisors LLC now owns 2,613 shares of the company’s stock worth $89,000 after acquiring an additional 469 shares in the last quarter. Institutional investors own 97.70% of the company’s stock.

Omnicell News Summary

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Zacks Research upgraded Omnicell from “hold” to “strong-buy,” adding to the bullish analyst-rating momentum. Tickerreport article
• Positive Sentiment: Zacks cited solid earnings-estimate revisions as a reason OMCL may continue moving higher in the near term. Zacks earnings-estimate revisions article
• Positive Sentiment: OMCL was added to Zacks’ Rank #1 (Strong Buy) lists for momentum and value stocks, reinforcing the favorable assessment. Zacks momentum stocks article Zacks value stocks article
• Neutral Sentiment: A Zacks article noted that analysts’ consensus target implies substantial potential upside, but cautioned that price targets alone have limited predictive value; it also pointed to estimate revisions as a more encouraging signal. Zacks analyst price-target article

Omnicell Company Profile

Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.

The company’s product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.